Condition: Locally Advanced or Metastatic Malignant Solid Tumors · Sponsor: Astellas Pharma Global Development, Inc.
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then attack the tumor cells in people with solid tumors. ASP2998 will either be given by itself, or given together with one or more of standard cancer treatments pembrolizumab, carboplatin, and enfortumab vedotin. This is an early development study to collect information about ASP2998 in people with solid tumors. In this study ASP2998 will be given to humans for the first time. Early development studies are mostly about safety, but also to find the most suitable dose. Other aims are to check if ASP2998 shows signs of reducing tumor growth, to learn how the body processes ASP2998, and to check if there are changes either in the TROP2 protein or in the immune system. The main aim of the study is to check the safety of ASP2998 when given by itself and given with the standard cancer treatments, and how well it is tolerated. People in this study will be adults with locally advanced, unresectable or metastatic solid tumors. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. People's cancer came back or became worse after previous treatment or they couldn't receive treatment. Some people who had previously refused treatment may be able to take part. This …
This description comes directly from the study's public registry record.
Astellas Pharma Global Development, Inc. · 800-888-7704 · Astellas.registration@astellas.com
Always discuss trial participation with your own doctor first.
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
| START New York Long Island | New Hyde Park, New York, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
| National Cancer Center Hospital East | Kashiwa-shi, Chiba, Japan | Recruiting |
| National Cancer Center Hospital | Chuo-ku, Tokyo, Japan | Recruiting |
| The Cancer Institute Hospital of JFCR | Koto-ku, Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07287995